Novo says semaglutide moved children under 12 below obesity threshold
Wegovy is not approved under age 12, and Novo must still file with the FDA before any on-label pediatric use in the United States.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 15 12:20 ETSource: 24/7 Wall St.
The wire
- 01In the Phase 3 STEP Young trial, weekly semaglutide plus diet and activity counseling met its primary BMI endpoint in children aged six to under twelve; Reuters reported no placebo participants fell below the clinical obesity threshold.
- 02A pediatric label would extend Wegovy into an age group tirzepatide has not reached, but payers rarely fund pediatric chronic injectables without long safety records.
- 03Durability after discontinuation is unstudied in this age group, and effects on growth, puberty timing and bone density will take years of follow-up to answer.
From the source
Read at 247wallst.comNovo Nordisk Expands Obesity Drug to Children, But Market Hesitates on Adoption
A landmark trial just proved semaglutide can pull children as young as six below the obesity threshold, yet Wall Street shrugged and the real battle over who pays, who prescribes, and whether society is ready has barely begun.